NOVONIX Limited filings document foreign-issuer reports furnished on Form 6-K, with exhibits drawn from ASX announcements and corporate notices. The record includes disclosures on annual general meeting presentations and voting results, material-event updates, material agreements, operating and financial results, and governance matters tied to the company's battery materials business.
Capital-structure filings cover applications for quotation of ordinary fully paid securities, securities issued from option exercises or convertible-security conversions, performance rights, and director interest notices. These filings also record shareholder voting matters and formal updates relevant to NOVONIX's ADR and foreign-issuer reporting framework.
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y notice showing a change in director Nicholas Liveris’s shareholding. The filing states that the change arose from an on‑market trade and that he now holds 559,090 ordinary shares as a direct interest.
NOVONIX LIMITED has issued 451,991 new ordinary fully paid shares (ASX code NVX) on 11/03/2026 following the conversion of performance rights under an employee incentive scheme. The shares were issued for non-cash consideration, with an estimated value of AUD 0.30 per share.
After this issue, the company has 861,365,155 NVX ordinary shares quoted on ASX. It also has unquoted performance rights, options with various terms, and convertible notes remaining on issue, which may lead to further share issuances if converted or exercised.
NOVONIX Limited filed a Form 6-K describing an exclusive access agreement to evaluate purchasing 17.5 acres of land directly adjacent to its Riverside anode materials facility in Chattanooga, Tennessee. The potential purchase price for the adjacent land is US$26.5 million, contingent on completing due diligence and deciding to proceed.
NOVONIX will pay US$100,000 for at least 150 days of exclusive due diligence and will assess whether the land can be re-zoned to heavy industrial use. The company states there is no certainty the transaction will proceed and will provide further updates under its continuous disclosure obligations.
NOVONIX Limited filed a Form 6-K describing an exclusive access agreement to evaluate purchasing 17.5 acres of land directly adjacent to its Riverside anode materials facility in Chattanooga, Tennessee. The potential purchase price for the adjacent land is US$26.5 million, contingent on completing due diligence and deciding to proceed.
NOVONIX will pay US$100,000 for at least 150 days of exclusive due diligence and will assess whether the land can be re-zoned to heavy industrial use. The company states there is no certainty the transaction will proceed and will provide further updates under its continuous disclosure obligations.
NOVONIX Limited filed a Form 6-K reporting an Appendix 3Y notice to the ASX about a change in a director’s shareholding. The notice shows director Nicholas Liveris now has a relevant interest in 589,142 ordinary shares held directly following an on-market trade.
The filing confirms there was no trading during a closed period that required prior written clearance.
NOVONIX Limited filed a Form 6-K reporting an Appendix 3Y notice to the ASX about a change in a director’s shareholding. The notice shows director Nicholas Liveris now has a relevant interest in 589,142 ordinary shares held directly following an on-market trade.
The filing confirms there was no trading during a closed period that required prior written clearance.
Novonix Limited reported a small increase in its share count after performance rights converted into ordinary shares. The company applied for quotation of 2,177 NVX ordinary fully paid shares on ASX, issued on 3 March 2026 from options or other convertible securities under an employee incentive scheme.
These new shares form part of an existing quoted class. Following this quotation, the company’s quoted ordinary shares total 860,913,164, alongside unquoted performance rights, options, and convertible notes that remain outstanding.
Novonix Limited filed a Form 6-K furnishing several Australian Appendix 3Y notices that update directors’ shareholdings after equity awards vested. For director Robert Natter, 120,594 share rights vested into 120,594 ordinary shares, reported as an indirect interest.
Director Anthony Bellas also saw 120,594 share rights vest into 120,594 ordinary shares, increasing his indirect holding via Loch to 2,398,145 ordinary shares, alongside other existing holdings. Directors Sharan Burrow, Ron Edmonds, Jean Oelwang and Nicholas Liveris reported higher ordinary share holdings following the issue of shares on vesting of share rights, with no trades during a closed period.
Novonix Limited filed a Form 6-K furnishing several Australian Appendix 3Y notices that update directors’ shareholdings after equity awards vested. For director Robert Natter, 120,594 share rights vested into 120,594 ordinary shares, reported as an indirect interest.
Director Anthony Bellas also saw 120,594 share rights vest into 120,594 ordinary shares, increasing his indirect holding via Loch to 2,398,145 ordinary shares, alongside other existing holdings. Directors Sharan Burrow, Ron Edmonds, Jean Oelwang and Nicholas Liveris reported higher ordinary share holdings following the issue of shares on vesting of share rights, with no trades during a closed period.
NOVONIX Limited reported the issue of 7,704,361 unquoted performance rights (ASX code NVXAD) under its employee incentive scheme. These rights are in an existing, unquoted class and are not intended to be listed on the ASX.
Following this grant, NOVONIX has 860,910,987 ordinary fully paid shares on issue, alongside various unquoted securities including 25,092,989 performance rights in total, options, share rights, and convertible notes. The company confirms the issue was made under an exception in ASX Listing Rule 7.2, meaning separate security holder approval was not required.
NOVONIX Limited reported the issue of 7,704,361 unquoted performance rights (ASX code NVXAD) under its employee incentive scheme. These rights are in an existing, unquoted class and are not intended to be listed on the ASX.
Following this grant, NOVONIX has 860,910,987 ordinary fully paid shares on issue, alongside various unquoted securities including 25,092,989 performance rights in total, options, share rights, and convertible notes. The company confirms the issue was made under an exception in ASX Listing Rule 7.2, meaning separate security holder approval was not required.
NOVONIX Limited reports its 2025 results, with revenue of $5,617,119, down 4%, and a net loss of $92,725,187, 24% lower than the prior year’s loss. Net tangible assets per security fell to $0.18 from $0.22. No dividends were paid or declared for 2025 or 2024.
The company ended 2025 with $79.9 million in cash, cash equivalents and short-term investments but continues to post significant operating cash outflows and discloses material uncertainty about its ability to continue as a going concern. NOVONIX has a $100 million U.S. Department of Energy grant, a conditional DOE loan commitment of up to $754.8 million, and a $103 million U.S. tax credit allocation to support its Chattanooga anode materials build-out.
Management also highlights a binding term sheet, signed after year-end, for the proposed sale of its Battery Technology Solutions business, which currently generates all revenue. If completed, NOVONIX expects to focus on establishing a vertically integrated synthetic graphite supply chain in North America.
NOVONIX Limited has issued 1,008,567 new ordinary fully paid shares (ASX code NVX) following the exercise or conversion of existing share rights (NVXAB). These additional shares are in a class already quoted on the ASX and rank equally with existing ordinary shares from the issue date of February 27, 2026.
The consideration for these shares is non-cash, with an estimated value of AUD 0.335 per share. After this issuance, NOVONIX has 860,910,987 ordinary fully paid shares on issue, alongside unquoted performance rights, options and convertible notes.
NOVONIX Limited files its annual report on Form 20‑F, highlighting a capital-intensive growth plan, significant losses and substantial funding needs. The company reported a net loss of $84.5 million for 2025 and held $79.9 million in cash, cash equivalents and short‑term investments, alongside net current assets of $3.9 million. Management warns of material uncertainty about its ability to continue as a going concern.
NOVONIX is scaling synthetic graphite anode production at its Riverside facility in Chattanooga using proprietary furnace technology and long‑term offtake relationships with Panasonic Energy and PowerCo, but faces equipment delays, technology scale‑up risk and dependence on limited suppliers such as Harper and select needle coke producers. It has a $100 million DOE grant and a conditional DOE ATVM loan commitment of up to $754.8 million, both requiring significant cost sharing and strict compliance, plus a $103 million 48C tax credit allocation.
The company has entered a binding term sheet, subject to definitive agreements and conditions, to sell its Battery Technology Solutions business, which currently generates all revenue; after a divestiture, NOVONIX would have no revenue until its anode materials business scales. The filing details extensive risk factors spanning funding, customer concentration, graphite market dynamics, regulatory compliance and cybersecurity.
NOVONIX Limited files its annual report on Form 20‑F, highlighting a capital-intensive growth plan, significant losses and substantial funding needs. The company reported a net loss of $84.5 million for 2025 and held $79.9 million in cash, cash equivalents and short‑term investments, alongside net current assets of $3.9 million. Management warns of material uncertainty about its ability to continue as a going concern.
NOVONIX is scaling synthetic graphite anode production at its Riverside facility in Chattanooga using proprietary furnace technology and long‑term offtake relationships with Panasonic Energy and PowerCo, but faces equipment delays, technology scale‑up risk and dependence on limited suppliers such as Harper and select needle coke producers. It has a $100 million DOE grant and a conditional DOE ATVM loan commitment of up to $754.8 million, both requiring significant cost sharing and strict compliance, plus a $103 million 48C tax credit allocation.
The company has entered a binding term sheet, subject to definitive agreements and conditions, to sell its Battery Technology Solutions business, which currently generates all revenue; after a divestiture, NOVONIX would have no revenue until its anode materials business scales. The filing details extensive risk factors spanning funding, customer concentration, graphite market dynamics, regulatory compliance and cybersecurity.